CLDN1 and ulcerative colitis: Devriese et al. (2017) also found that reduced mucosa-associated Butyricicoccus activity in patients with ulcerative colitis was correlated with aberrant expressions of claudin-1, supporting its use as a pharmabiotic that preserves epithelial tight junction integrity.